INTELLIGENT BIO SOLUTIONS INC. 8-K

What Happened

• Intelligent Bio Solutions Inc. (INBS) filed an 8-K on March 23, 2026 reporting that its Compensation Committee and Board approved time-vesting and performance-vesting restricted stock awards to executives, directors and employees effective March 18, 2026.
• The Company also filed a prospectus supplement to its existing “shelf” registration/ATM program, making additional shares available for sale under the ATM agreement with Ladenburg Thalmann.

Key Details

• Executive awards: CEO Harry Simeonidis and CFO Spiro Sakiris each received 9,150 time-vesting shares (vesting on the 48-month anniversary) and 21,350 performance-vesting shares.
• Performance vesting schedule: 30% tied to a clinical trial milestone, 40% tied to a specified FDA regulatory submission, 30% tied to a commercial supply/sales milestone; any unmet performance conditions lapse after 10 years. Vesting for each tranche occurs on the later of the milestone certification and the one-year anniversary of the grant, and is subject to continued service.
• Other grants: 20,000 aggregate time-vesting shares to non-employee directors (12-month vest), 10,500 aggregate time-vesting shares to non-executive employees (48-month vest), and 24,500 aggregate performance-vesting shares to non-executive employees.
• Shares outstanding and ATM update: after these issuances and warrant exercises, common shares outstanding were 2,001,173 as of March 23, 2026. The Company’s March 23, 2026 ATM supplement makes additional shares available for gross proceeds up to $3,966,316 under the effective Form S-3 shelf (previous 2025 ATM supplement covered $1,211,174).
• Administrative terms: awards use new AUS/UK and U.S. award agreement forms, include dividend accumulation on unvested shares, are subject to clawback and tax withholding, and Australian participants face additional post-vesting sale restrictions under an Australian Sub-Plan.

Why It Matters

• These awards provide multi-year retention and performance incentives for key executives and staff; the performance-based structure ties equity payout to clinical, regulatory and commercial milestones relevant to the company’s development path.
• For investors, the filing signals potential future dilution: the company has ~2.0M shares outstanding and an ATM facility that could raise up to $3.97M of gross proceeds (actual share dilution depends on future sale prices).
• The details (vesting timelines, 10-year performance window, and Australian sale restrictions) define when equity may convert to freely tradable shares, which matters for timing of dilution and insider alignment with corporate milestones.